8 November 2024 Amid the escalating geopolitical issues coupled with the uncertainty in global trades cause a noticeable impact on Pentamaster’s 3Q24 performance. As a result, the company experienced slower than expected growth in certain downstream customers and reported a
CROSBY Research – Pentamaster International (1665 HK/ BUY): Medical devices’ growth momentum remained strong in 9M24
